Search

Your search keyword '"Salles, Gille"' showing total 5 results
Start Over Author "Salles, Gille" Topic oncology
5 results on '"Salles, Gille"'

1. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Author

Jasmine Zain, Robert Orlowski, Philippe Armand, Guilherme Fleury Perini, Arun Balakumaran, Jakub Svoboda, Jing Ouyang, Pier Luigi Zinzani, Pei-Hsuan Chen, Vincent Ribrag, Catherine Thieblemont, Vladimir Melnichenko, Gayane Tumyan, Azra H. Ligon, Gilles Salles, Margaret A. Shipp, Maria D Caballero, Muhit Ozcan, Beth Christian, Zafer Gulbas, Donna Neuberg, Jan Walewski, Robert A. Redd, Arkendu Chatterjee, Sanjay R. Patel, Sergio Portino, Scott J. Rodig, Kamal Bouabdallah, Laura Fogliatto, Armand, Philippe, Rodig, Scott, Melnichenko, Vladimir, Thieblemont, Catherine, Bouabdallah, Kamal, Tumyan, Gayane, Özcan, Muhit, Portino, Sergio, Fogliatto, Laura, Caballero, Maria D, Walewski, Jan, Gulbas, Zafer, Ribrag, Vincent, Christian, Beth, Perini, Guilherme Fleury, Salles, Gille, Svoboda, Jakub, Zain, Jasmine, Patel, Sanjay, Chen, Pei-Hsuan, Ligon, Azra H, Ouyang, Jing, Neuberg, Donna, Redd, Robert, Chatterjee, Arkendu, Balakumaran, Arun, Orlowski, Robert, Shipp, Margaret, and Zinzani, Pier Luigi

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Poor prognosis, Lymphoma, B-Cell, Time Factors, Pembrolizumab, Antibodies, Monoclonal, Humanized, Mediastinal Neoplasms, Risk Assessment, Unmet needs, Young Adult, Antineoplastic Agents, Immunological, Refractory, Risk Factors, Internal medicine, Hematologic Malignancy, medicine, Humans, Primary Mediastinal Large B-Cell Lymphoma, Progression-free survival, Pembrolizumab, Relapsed, Refractory Primary Mediastinal Large B-Cell Lymphoma, business.industry, ORIGINAL REPORTS, Middle Aged, South America, medicine.disease, Progression-Free Survival, United States, Lymphoma, Europe, Editorial Commentary, Drug Resistance, Neoplasm, Monoclonal, Disease Progression, Female, Neoplasm Recurrence, Local, business
Abstract

PURPOSE Patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) have a poor prognosis, and their treatment represents an urgent and unmet need. Because PMBCL is associated with genetic aberrations at 9p24 and overexpression of programmed cell death-1 (PD-1) ligands (PD-L1), it is hypothesized to be susceptible to PD-1 blockade. METHODS In the phase IB KEYNOTE-013 (ClinicalTrials.gov identifier: NCT01953692 ) and phase II KEYNOTE-170 (ClinicalTrials.gov identifier: NCT02576990 ) studies, adults with rrPMBCL received pembrolizumab for up to 2 years or until disease progression or unacceptable toxicity. The primary end points were safety and objective response rate in KEYNOTE-013 and objective response rate in KEYNOTE-170. Secondary end points included duration of response, progression-free survival, overall survival, and safety. Exploratory end points included association between biomarkers and pembrolizumab activity. RESULTS The objective response rate was 48% (7 complete responses; 33%) among 21 patients in KEYNOTE-013 and 45% (7 complete responses; 13%) among 53 patients in KEYNOTE-170. After a median follow-up time of 29.1 months in KEYNOTE-013 and 12.5 months in KEYNOTE-170, the median duration of response was not reached in either study. No patient with complete response experienced progression, including 2 patients with complete response for at least 1 year off therapy. Treatment-related adverse events occurred in 24% of patients in KEYNOTE-013 and 23% of patients in KEYNOTE-170. There were no treatment-related deaths. Among 42 evaluable patients, the magnitude of the 9p24 gene abnormality was associated with PD-L1 expression, which was itself significantly associated with progression-free survival. CONCLUSION Pembrolizumab is associated with high response rate, durable activity, and a manageable safety profile in patients with rrPMBCL.

Published
2019

2. No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib

Author

Paolo Ghia, Oksana Gurtovaya, Guan Xing, Jacqueline C. Barrientos, John M. Pagel, Bianca Ruzicka, Peter Hillmen, Jeff P. Sharman, Gilles Salles, Pankaj Bhargava, Stephan Stilgenbauer, Barrientos, Jacqueline C, Hillmen, Peter, Salles, Gille, Sharman, Jeff, Stilgenbauer, Stephan, Gurtovaya, Oksana, Xing, Guan, Ruzicka, Bianca, Bhargava, Pankaj, Ghia, Paolo, and Pagel, John M

Subjects
Oncology, Cancer Research, medicine.medical_specialty, medicine.drug_class, Hemorrhage, thrombocytopenia, Antineoplastic Agents, PI3K inhibitor, Relapsed chronic lymphocytic leukemia, antiplatelet, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Indolent Non-Hodgkin Lymphoma, Medicine, Humans, In patient, Quinazolinones, business.industry, Lymphoma, Non-Hodgkin, Anticoagulant, anticoagulant, Hematology, Leukemia, Lymphocytic, Chronic, B-Cell, chemistry, Purines, 030220 oncology & carcinogenesis, Concomitant, Ibrutinib, sense organs, business, Idelalisib, 030215 immunology
Abstract

The advent of novel B-cell receptor pathway targeting agents like ibrutinib dramatically changed management of B-cell malignancies. However, with concomitant anticoagulation (AC) and antiplatelet (AP) therapy, ibrutinib is associated with increased bleeding. This post hoc analysis aimed to determine the role of AC/AP therapy in patients with idelalisib-treated B-cell malignancies and to establish if it contributes to increased bleeding events. Data from two idelalisib trials (rituximab ± idelalisib in chronic lymphocytic leukemia [CLL] and idelalisib monotherapy in indolent non-Hodgkin lymphoma [iNHL]) were analyzed. Antithrombotic therapy was common (36%-63%), with comparable bleeding incidence across treatment groups (14%-19%; p = 0.56). Bleeding events of grade ≥3 occurred in 0.9% and 3.2% of the idelalisib-treated CLL and iNHL cohorts, respectively. Our findings demonstrate no increase in bleeding events with simultaneous AC/AP treatment and idelalisib use. Hemorrhagic risk is prevalent in these patients and an important consideration when evaluating available treatment options. ClinicalTrials.gov identifiers: NCT01539512 and NCT01282424.

Published
2020

3. HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes

Author

Roel Vermeulen, Paulo Bofetta, Nicole Wong Doo, Mark P. Purdue, Eleanor Kane, Gilles Salles, Bengt Glimelius, Christine F. Skibola, Tongzhang Zheng, Graham G. Giles, Scott Davis, Pierluigi Cocco, Karin E. Smedby, Melissa C. Southey, Alexandra Nieters, Elizabeth A. Holly, Corrado Magnani, Paul Brennan, Stephanie J. Lax, David G. Cox, Lindsay M. Morton, Nikolaus Becker, Qing Lan, Elio Riboli, Herve Ghesquieres, Rudolph Kaaks, Jennifer Turner, Martha S. Linet, Anne Kricker, Stephanie J. Weinstein, Christopher R. Flowers, Alain Monnereau, Silvia de Sanjosé, Mary Carrington, John J. Spinelli, Patricia Hartge, Nathaniel Rothman, Yolanda Benavente, Susan L. Slager, Martha Glenn, Richard K. Severson, Ora Paltiel, Yawei Zhang, Ruth C. Travis, Demetrius Albanes, Nicola J. Camp, Paige M. Bracci, Jacqueline Clavel, James R. Cerhan, Marc Maynadié, Maria Grazia Ennas, Marie Hélène Delfau-Larue, Peter Kraft, Henrik Hjalgrim, Roger L. Milne, Alan A. Arslan, Jacob Musinsky, Martyn T. Smith, Anthony Staines, Lauren R. Teras, Jenna M. Voutsinas, Lenka Foretova, Sophia S. Wang, Hans-Olov Adami, Andrew L. Feldman, Wendy Cozen, Angela Brooks-Wilson, Kenneth Offit, Brian K. Link, Brenda M. Birmann, Sonja I. Berndt, Stephen J. Chanock, James McKay, Dennis D. Weisenburger, Claire M. Vajdic, Giancarlo Latte, Karen Curtin, W. Ryan Diver, Mads Melbye, Lucia Conde, Elizabeth E. Brown, Joseph Vijai, Eve Roman, Wang, Sophia S., Carrington, Mary, Berndt, Sonja I., Slager, Susan L., Bracci, Paige M., Voutsinas, Jenna, Cerhan, James R., Smedby, Karin E., Hjalgrim, Henrik, Vijai, Joseph, Morton, Lindsay M., Vermeulen, Roel, Paltiel, Ora, Vajdic, Claire M., Linet, Martha S., Nieters, Alexandra, de Sanjose, Silvia, Cozen, Wendy, Brown, Elizabeth E., Turner, Jennifer, Spinelli, John J., Zheng, Tongzhang, Birmann, Brenda M., Flowers, Christopher R., Becker, Nikolau, Holly, Elizabeth A., Kane, Eleanor, Weisenburger, Denni, Maynadie, Marc, Cocco, Pierluigi, Albanes, Demetriu, Weinstein, Stephanie J., Teras, Lauren R., Diver, W. Ryan, Lax, Stephanie J., Travis, Ruth C., Kaaks, Rudolph, Riboli, Elio, Benavente, Yolanda, Brennan, Paul, McKay, Jame, Delfau-Larue, Marie-Hélène, Link, Brian K., Magnani, Corrado, Ennas, Maria Grazia, Latte, Giancarlo, Feldman, Andrew L., Doo, Nicole Wong, Giles, Graham G., Southey, Melissa C., Milne, Roger L., Offit, Kenneth, Musinsky, Jacob, Arslan, Alan A., Purdue, Mark P., Adami, Hans-Olov, Melbye, Mad, Glimelius, Bengt, Conde, Lucia, Camp, Nicola J., Glenn, Martha, Curtin, Karen, Clavel, Jacqueline, Monnereau, Alain, Cox, David G., Ghesquières, Hervé, Salles, Gille, Boffetta, Paolo, Foretova, Lenka, Staines, Anthony, Davis, Scott, Severson, Richard K., Lan, Qing, Brooks-Wilson, Angela, Smith, Martyn T., Roman, Eve, Kricker, Anne, Zhang, Yawei, Kraft, Peter, Chanock, Stephen J., Rothman, Nathaniel, Hartge, Patricia, and Skibola, Christine F.

Subjects
Male, 0301 basic medicine, Heterozygote, Cancer Research, medicine.medical_specialty, SUSCEPTIBILITY LOCI, Chronic lymphocytic leukemia, EPIDEMIOLOGIC RESEARCH, Genome-wide association study, Human leukocyte antigen, Biology, CLASSIFICATION, ANTIGENS, Article, Genetic Heterogeneity, 03 medical and health sciences, immune system diseases, hemic and lymphatic diseases, Internal medicine, medicine, INTERLYMPH, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Prospective Studies, GENOME-WIDE ASSOCIATION, Allele, HLA Complex, Science & Technology, Hematology, CHRONIC LYMPHOCYTIC-LEUKEMIA, Genetic heterogeneity, Lymphoma, Non-Hodgkin, Histocompatibility Antigens Class I, Histocompatibility Antigens Class II, HETEROZYGOTE ADVANTAGE, medicine.disease, 3. Good health, Lymphoma, 030104 developmental biology, Oncology, Case-Control Studies, Immunology, B-VIRUS INFECTION, Female, Life Sciences & Biomedicine, NEOPLASMS, Genome-Wide Association Study
Abstract

A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of “heterozygote advantage” regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL = 1.31, 95% CI = 1.06–1.60; OR MZL = 1.45, 95% CI = 1.12–1.89) and class II HLA-DRB1 locus (OR DLBCL = 2.10, 95% CI = 1.24–3.55; OR MZL = 2.10, 95% CI = 0.99–4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (P trend < 0.0001, FDR = 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes. Significance: HLA gene diversity reduces risk for non-Hodgkin lymphoma. Cancer Res; 78(14); 4086–96. ©2018 AACR.

Published
2018

4. Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries

Author

Antonio Rueda, Bastian von Tresckow, Graham P. Collins, Gilles Salles, Francesco Zaja, Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Collins, Graham P., Rueda, Antonio, Salles, Gille, von Tresckow, Bastian, Zaja, Francesco, Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )

Subjects
BEACOPP, Male, Cancer Research, autologous stem cell transplantation, Immunoconjugates, medicine.medical_treatment, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Autologous stem-cell transplantation, Germany, Outcome Assessment, Health Care, Brentuximab vedotin, Child, ComputingMilieux_MISCELLANEOUS, Aged, 80 and over, Brentuximab Vedotin, Hematology, Middle Aged, Combined Modality Therapy, Hodgkin Disease, Europe, Oncology, Italy, 030220 oncology & carcinogenesis, Child, Preschool, Female, France, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Transplantation, Autologous, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Refractory Hodgkin Lymphoma, Humans, Aged, Retrospective Studies, Chemotherapy, CD30, Hodgkin lymphoma, real-world data, business.industry, Guideline, United Kingdom, Transplantation, ABVD, Spain, business, 030215 immunology, Stem Cell Transplantation
Abstract

We examined real-world data on management of relapsed/refractory Hodgkin lymphoma (R/R HL) in five European countries and the consistency of these data with guideline recommendations. Retrospective clinical and epidemiologic data for 509 patients with R/R HL treated between January 2014 and March 2015 were collected at centers in France, Germany, Italy, Spain, and the United Kingdom. Mean age was 46.3 years; 73.3% were receiving second-line therapy for a first relapse during the reporting period. Most patients received ABVD as front-line chemotherapy, except in Germany where escalated BEACOPP was used more often. The proportion of patients receiving stem cell transplantation (SCT) was 44%; 85% of transplants occurred at first relapse. Brentuximab vedotin (BV) was usually administered after autologous SCT, and was initiated for 65% of patients following SCT failure. Our findings suggest that R/R HL management across these countries is broadly consistent with guideline recommendations and that BV is well-integrated into treatment pathways.

Published
2018

5. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma : a subgroup analysis of a phase 2 study

Author

Sanatan Shreay, Ian W. Flinn, Andreas Viardot, Yeonhee Kim, Matthias Will, Peter Martin, Gilles Salles, Madlaina Breuleux, Stephen J. Schuster, Bess Sorensen, Wojciech Jurczak, Nina D. Wagner-Johnston, Christopher R. Flowers, Kristie A. Blum, Brad S. Kahl, Sven de Vos, Ajay K. Gopal, Pier Luigi Zinzani, Salles, Gille, Schuster, Stephen J., De Vos, Sven, Wagner-Johnston, Nina D., Viardot, Andrea, Blum, Kristie A., Flowers, Christopher R., Jurczak, Wojciech J., Flinn, Ian W., Kahl, Brad S., Martin, Peter, Kim, Yeonhee, Shreay, Sanatan, Will, Matthia, Sorensen, Be, Breuleux, Madlaina, Zinzani, Pier Luigi, Gopal, Ajay K, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Division of Hematology-Oncology [New York], Weill Medical College of Cornell University [New York], and L. and A. Seràgnoli Hospital, University of Bologna

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Pathology, Lymphoma, Patients, analysis, Follicular lymphoma, Phases of clinical research, [SDV.CAN]Life Sciences [q-bio]/Cancer, Subgroup analysis, Medical Oncology, Time, 03 medical and health sciences, 0302 clinical medicine, immune system diseases, Germany, hemic and lymphatic diseases, Internal medicine, medicine, Online Only Articles, ComputingMilieux_MISCELLANEOUS, Hematology, business.industry, medicine.disease, 3. Good health, 030104 developmental biology, Italy, 030220 oncology & carcinogenesis, Medicine, Rituximab, France, Refractory Follicular Lymphoma, business, Idelalisib, medicine.drug
Abstract

Approximately 20% of all non-Hodgkin lymphoma (NHL) and 60% of indolent NHL (iNHL) cases are follicular lymphoma (FL),[1][1],[2][2] a disease considered treatable, but not curable, with currently available therapeutic options.[3][3] While survival in patients with FL has improved with the

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results